Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls
Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls
NCT ID: NCT02809222 Phase: NA Status: COMPLETED Enrollment: 138 Completion: 2021-03-01
Conditions
Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Samples, Quality of life questionnaire
Summary
Myelodysplastic syndromes (MDS) is a group of heterogeneous diseases characterised by the clonal evolution of dysplastic hematopoietic stem cells. This evolution is associated with accumulation of cytogenetic mutations which leads to acute myeloid leukaemia (AML). Evolution of MDS is also associated with increase of reactive oxygen species (ROS). The increase of ROS is associated with accumulation of cytogenetic mutations. Ascorbic acid (AA) is an actor of the regulation of the oxidative metabolism in the human body.
Studies showed that supplementation with AA can change the proliferation status of MDS cells. Adjuvant treatment with AA is associated with a beneficial effect on the evolution of MDS and AML. The present study aim at describing the variations of plasmatic ascorbic acid concentrations between healthy volunteers and patients with myelodysplastic syndromes advanced in their treatment or recently diagnosed during a follow-up of 12 months.
Primary Outcome
Plasmatic ascorbic acid concentration at baseline